Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide-dexamethasone alone or with standard multiple myeloma regimens in transplant-ineligible newly diagnosed multiple myeloma
2024-518870-15-00Phase 2Authorised
- Sponsor
- PETHEMA
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide, daratumumab and dexamethasone in multiple myeloma (MM), sponsored by PETHEMA. Planned start Nov 2024; status: authorised.
02
Drugs
iberdomidedaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-518870-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518870-15-00.